Merck to Acquire Verona Pharma in $10 Billion Deal, Adding Ohtuvayre® to Strengthen Respiratory Portfolio and Expand Long-Term Growth in COPD Market Merck & Co., known as MSD outside the U.S. and Canada, today announced a definitive agreement to acquire…
Acadia Pharmaceuticals Grants Equity Awards to New Hires Under Nasdaq Rule 5635(c)(4) Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders…
Manitoba Bioscience Association Backs Government Plan to Boost Research and Clinical Trials Bioscience Association Manitoba (BAM) has voiced strong support for a major new initiative from the Manitoba government aimed at advancing health research and clinical trials across the province.…
Biotech Executives and Investors Urge FDA to Preserve Access to Mifepristone Amid Legal Uncertainty A group of leading biotechnology executives, investors, and scientific experts are urging the U.S. Food and Drug Administration (FDA) to safeguard continued access to mifepristone, a…
Sunshine Biopharma Launches NIOPEG® Biosimilar in Canada, Targeting $10B Biologics Market Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies, and other therapeutic areas, has announced the commercial launch of…
OXLUMO® (Lumasiran) Secures National Reimbursement in Canada for Treatment of Primary Hyperoxaluria Type 1 Alnylam Canada ULC has announced that OXLUMO® (lumasiran), a first-in-class RNA interference (RNAi) therapeutic, is now funded across Canada through both public and private healthcare plans.…
Jazz Pharmaceuticals Secures Conditional EU Approval for Ziihera® (zanidatamab) to Treat Advanced HER2-Positive Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that the European Commission (EC) has granted conditional marketing authorization for Ziihera® (zanidatamab), a dual HER2-targeted bispecific…
Genmab Announces Leadership Transition as Chief Legal Officer Birgitte Stephensen Retires, Greg Mueller Appointed Successor Genmab A/S (Nasdaq: GMAB), a leading international biotechnology company focused on antibody-based therapeutics for cancer and other serious diseases, today announced a major leadership transition…
Takeda Secures FDA Approval for GAMMAGARD LIQUID ERC, the First Ready-to-Use Liquid Immunoglobulin Therapy with Low IgA Content Takeda (TSE:4502/NYSE:TAK) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for GAMMAGARD LIQUID ERC [immune globulin infusion…
Merck Finalizes $3.4 Billion Acquisition of SpringWorks Therapeutics to Strengthen Rare Tumor Portfolio and Drive Sustainable Healthcare Growth Merck, a global leader in science and technology, today announced the successful completion of its acquisition of SpringWorks Therapeutics, Inc. for an…
Vertex Gains EU Approval for ALYFTREK®, a Next-Generation CFTR Modulator for Cystic Fibrosis Patients Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the European Commission has granted marketing authorization for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a new, once-daily triple-combination CFTR modulator therapy for the…
Riliprubart Receives Orphan Drug Designation in Japan for Chronic Inflammatory Demyelinating Polyneuropathy Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to riliprubart, an investigational monoclonal antibody that targets activated C1s in the…